Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 19.25M P/E - EPS this Y - Ern Qtrly Grth -
Income -26.17M Forward P/E - EPS next Y - 50D Avg Chg 13.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 32.00%
Dividend N/A Price/Book 0.86 EPS next 5Y - 52W High Chg -53.00%
Recommedations - Quick Ratio 1.39 Shares Outstanding 55.22M 52W Low Chg 217.00%
Insider Own 29.80% ROA -44.91% Shares Float 32.39M Beta 1.31
Inst Own 25.52% ROE -216.99% Shares Shorted/Prior 155.07K/442.65K Price 0.42
Gross Margin - Profit Margin - Avg. Volume 178,893 Target Price -
Oper. Margin - Earnings Date May 10 Volume 16,114 Change -2.10%
About BiomX Inc.

BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

BiomX Inc. News
04/23/24 BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)
04/18/24 BiomX Announces the Appointment of Susan Blum to its Board of Directors
04/05/24 Here's Why BiomX (PHGE) Is a Great 'Buy the Bottom' Stock Now
04/04/24 BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure
04/03/24 BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
03/27/24 BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024
03/18/24 BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing
03/06/24 BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing
01/04/24 BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis
11/30/23 BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023
11/29/23 BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis
11/14/23 BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update
10/27/23 BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the 37th Annual North American Cystic Fibrosis Conference
10/18/23 BiomX Announces the Appointment of Edward L. Williams to its Board of Directors
10/04/23 BiomX Announces Completion of Patient Dosing in Part 2 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis
09/07/23 BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the European Respiratory Society (ERS) International Congress 2023
09/06/23 BiomX to Present at H.C. Wainwright 25th Annual Global Investment Conference
08/09/23 BiomX Reports Second Quarter 2023 Financial Results and Provides Business Update
08/02/23 BiomX to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 9th, 2023
06/08/23 NYSE American Initiates Delisting Proceedings for BiomX Warrants
PHGE Chatroom

User Image Americanbulls Posted - 3 days ago

$PHGE may go up 24% if the bull pattern is confirmed. Check confirmation [46%] @ www.Americanbulls.com/SignalPage.aspx?lang=en&Ticker=PHGE. Buy level:0.36.

User Image ANTHONYMOMO Posted - 04/30/24

$PHGE GV $0.20 small float and big assets $91M moving like PHGE

User Image Convinvestor Posted - 04/30/24

$PHGE no one here? This seems to have so much potential. Thought this would be more active.

User Image VrtcIl Posted - 04/30/24

$PHGE still gaining momentum towards 1$. The uptrend is supported by consistent bigger highs and bigger lows, with notable volume signaling increased buying interest. Price: 0.5 Float: 29.1M Short Float: 0.8 % 💰 Dollar Volume: 2.0K ℹ️ Israel | Biotechnology

User Image RollingDollar Posted - 04/30/24

$PHGE

User Image RollingDollar Posted - 04/30/24

$PHGE

User Image DonCorleone77 Posted - 04/29/24

$PHGE BiomX files to sell 120.15M warrants to buy common stock for holders

User Image VrtcIl Posted - 04/29/24

$PHGE is one to watch for the day and maybe the following days as well if it manages to keep holding up. But never blindly enter and be patient for entry points with a defined risk. Price: 0.4 Float: 29.1M Short Float: 1.1 % 💰 Dollar Volume: 15.4K ℹ️ Israel | Biotechnology

User Image RollingDollar Posted - 04/29/24

$PHGE

User Image DuckITMan Posted - 04/23/24

$ICU And $PHGE the March to $2 and higher.

User Image RollingDollar Posted - 04/23/24

$PHGE

User Image DuckITMan Posted - 04/23/24

$ICU $NXPL $HUBC $PHGE all are Simmering Nicely and Longshot SPAC Play $FRZT Summer of Love!!!

User Image DuckITMan Posted - 04/23/24

$PHGE and $ICU looking to be Strengthening Momentum for some big Spikes....

User Image RollingDollar Posted - 04/23/24

$PHGE

User Image RollingDollar Posted - 04/23/24

$PHGE

User Image Stock_Titan Posted - 04/23/24

$PHGE BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024) https://www.stocktitan.net/news/PHGE/biom-x-to-present-data-from-phase-1b-2a-study-of-bx004-for-the-c3tvwbp9exva.html

User Image DuckITMan Posted - 04/22/24

$PHGE By the End of Summer who gets to $1 first $ICU, $FRZT, $PHGE $NUWE Surprise, Surprise, Surprise....

User Image jctataio Posted - 04/22/24

$MTTR $PHGE $EBS $TCON 🔥🔥🚨🚨

User Image DuckITMan Posted - 04/21/24

$ICU If the SEC Gonna Spy then Everyone Should Know $ICU is a Great Value Play. I Also like $HUBC, $PHGE, $FRZT, $NXPL and long shot $BETSF Revival https://nypost.com/2024/04/21/us-news/sec-illegally-tracking-americans-who-invests-in-the-stock-market-lawsuit-claims/?utm_medium=social&utm_source=twitter&utm_campaign=nypost

User Image Manamoney Posted - 04/16/24

$PHGE Why the hell does it keep on dropping ??? There are no bad news...

User Image StocksKing001 Posted - 04/14/24

$PHGE Here's Why BiomX (PHGE) Is a Great 'Buy the Bottom' Stock Now https://finance.yahoo.com/news/heres-why-biomx-phge-great-135503068.html

User Image RallyRaider Posted - 1 month ago

$PHGE so many sticks in the soup here.. sloppy merger. Can only ever be played for a pump.

User Image WolfofFraudStreet Posted - 1 month ago

$PHGE Was is a a fake merger or what is the deal with this?

User Image Stock_Titan Posted - 1 month ago

$PHGE BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure https://www.stocktitan.net/news/PHGE/biom-x-announces-compliance-with-nyse-guidelines-on-audit-opinion-03p1g5qngj5j.html

User Image Manamoney Posted - 1 month ago

$PHGE

User Image mikesterz7 Posted - 1 month ago

$PHGE Patient Screening Completed in Part 2 of Phase 1b/2a Trial of BX004 with patient enrollment expected to exceed original estimates FDA grants BX004 Fast Track designation Initial Data from Part 2 Now Expected in November 2023

User Image Gonzo214 Posted - 1 month ago

$PHGE looks like only catalysts are a meeting with FDA middle of year and then a couple of conferences. Outside of that, waiting for results early 2025. Seems like they have cash to make there. I’m all for fat people keeping limbs, so will stick around.

User Image epsguid Posted - 1 month ago

$PHGE reported a loss of $0.08 via @eWhispers http://eps.sh/d/phge

User Image Stock_Titan Posted - 1 month ago

$PHGE BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update https://www.stocktitan.net/news/PHGE/biom-x-reports-fourth-quarter-and-full-year-2023-financial-results-ryrz52qp16el.html

User Image me391 Posted - 1 month ago

$PHGE are earnings supposed to be bad? What happened? Or is this FUD selling?

Analyst Ratings
HC Wainwright & Co. Buy Apr 22, 24
HC Wainwright & Co. Buy Apr 3, 24
HC Wainwright & Co. Buy Mar 7, 24
HC Wainwright & Co. Buy Nov 14, 23
HC Wainwright & Co. Buy Aug 9, 23
HC Wainwright & Co. Buy May 15, 23
Chardan Capital Buy Nov 10, 22
Chardan Capital Buy May 24, 22
Ladenburg Thalmann Buy May 12, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Oron Assaf Chief Business Offic.. Chief Business Officer May 22 Buy 0.2731 3,192 872 10,914 05/24/23
OrbiMed Israel BioFund GP Limi... 10% Owner 10% Owner Feb 27 Buy 0.245 348,000 85,260 3,161,489 03/17/23
Ugwumba Chidozie Other Other Oct 17 Sell 0.36 74,955 26,984 2,997,025 11/14/22
Ugwumba Chidozie Other Other Aug 10 Sell 0.62 288,619 178,944 3,349,227 11/14/22